Get the Stockscreener App
20.66
1.90%
-0.40
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Innoviva Inc stock is traded at $20.66, with a volume of 978.55K.
It is down -1.90% in the last 24 hours and up +2.08% over the past month.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
See More
Previous Close:
$21.06
Open:
$20.88
24h Volume:
978.55K
Relative Volume:
1.58
Market Cap:
$1.49B
Revenue:
$434.49M
Net Income/Loss:
$504.34M
P/E Ratio:
3.4354
EPS:
6.0138
Net Cash Flow:
$181.97M
1W Performance:
-0.58%
1M Performance:
+2.08%
6M Performance:
-12.01%
1Y Performance:
+13.14%
1-Day Range:
$20.51
$20.94
1-Week Range:
$20.51
$21.49
52-Week Range:
$17.45
$25.14
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
20.66 | 1.49B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Resumed | Oppenheimer | Outperform |
| Feb-17-26 | Initiated | BTIG Research | Buy |
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026 - Stock Titan
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
INVA vs. MRK: Which Stock Is the Better Value Option? - Zacks Investment Research
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential - Zacks Investment Research
Should Value Investors Buy Innoviva (INVA) Stock? - Zacks Investment Research
Understanding Momentum Shifts in (INVA) - Stock Traders Daily
Innoviva at Cantor conference: growth bets beyond COPD royalties - investing.com
Innoviva at Cantor conference: growth bets beyond COPD royalties By Investing.com - Investing.com India
INVA - Finviz
Innoviva to Participate in Upcoming September 2026 Investor Conferences - biospace.com
Innoviva to Participate in Upcoming Investor Conferences - finance.yahoo.com
INVA Q2 2026 Earnings: EPS Misses by 356% as Loss Hits $1.14Consensus Forecast Report - vinanet.vn
(INVA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Entasis Therapeutics Holdings Inc. (ETTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Innoviva CEO Pavel Raifeld Executes Tax-Related Share Withholding Transaction - Kalkine Media
Innoviva (NASDAQ: INVA) CFO now holds 88,013 shares after tax withholding - Stock Titan
Innoviva (NASDAQ: INVA) CEO sees 1,130 shares withheld for taxes - Stock Titan
Innoviva CFO Stephen Basso Reports Share Withholding Transaction to Cover Taxes on August 2026 Equity Vesting - Kalkine Media
Cantor Fitzgerald reiterates Innoviva stock rating at overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Innoviva stock rating at overweight - Investing.com
Cantor Fitzgerald reiterates Innoviva stock rating at overweight By Investing.com - Investing.com UK
NewEdge Wealth LLC Acquires New Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva, Inc. (NASDAQ:INVA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Innoviva (INVA) Snapshot: Posts a 2.23% Loss to $21.00 in Latest Trading; the Session Ends Within the Reported Technical Boundaries on the DayWedge Breakout - vinanet.vn
Innoviva (INVA) Snapshot: Posts a 2.23% Loss to $21.00 in Latest Trading; the Session Ends Within the Reported Technical Boundaries on the DayWedge Breakout - dars.gov.et
70,000 Shares in Innoviva, Inc. $INVA Purchased by Chase Investment Counsel Corp - MarketBeat
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA) - simplywall.st
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA) - simplywall.st
Innoviva, Inc.: Target Price Consensus and Analysts Recommendations | INVA | US45781M1018 - marketscreener.com
Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva (INVA) Holds Near $20.87 After Modest 0.29% GainSuperTrend - vinanet.vn
Innoviva (INVA) Holds Near $20.87 After Modest 0.29% GainSupply Zone - dars.gov.et
Innoviva, Inc. (INVA) Stock Forecasts - Yahoo! Finance Canada
Innoviva (INVA) Holds Near $20.81 as Biopharma Royalty Stock Stays RangeboundVolatility Smile - vinanet.vn
Innoviva, Inc. (INVA) Stock Forecasts - Yahoo Finance
HC Wainwright Issues Positive Forecast for Innoviva Earnings - MarketBeat
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com Australia
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com India
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com Canada
Three Innoviva therapies named finalists for Prix Galien award - Investing.com
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com UK
Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award - Business Wire
Innoviva, Inc. (INVA) Stock Analysis: Uncovering a 69% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
How (INVA) Movements Inform Risk Allocation Models - Stock Traders Daily
Innoviva (INVA) Holds Steady at $20.68: Key Support and Resistance in FocusJelly Roll Trade - dars.gov.et
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA? - webull.com
Innoviva, Inc. (INVA) Stock Forecasts - Yahoo! Finance Canada
Innoviva stock price target reiterated at $46 by H.C. Wainwright - Investing.com Nigeria
Innoviva stock price target reiterated at $46 by H.C. Wainwright - Investing.com
Innoviva stock price target reiterated at $46 by H.C. Wainwright - Investing.com UK
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
3.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):